Authors
Ajay K. Gopal, MD, FACP, is the medical director for Hematology, Malignancies/Hematology, the clinical research director for the Lymphoma Program and an professor in the Clinical Research Division at Fred Hutch Cancer Center; professor of Hematology and Oncology in the Division of Hematology and Oncology at the University of Washington School of Medicine, and the Stephen Hans Petersdorf, MD, Endowed Chair in Cancer Care at the University of Washington Medicine, both located in Washington.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5


